FOLLOWUS
1. Department of Dermatology First Affiliated Hospital and Institute of Mycology, Jinan University,Guangzhou,China
2. Department of Dermatology Shenzhen Shajing Affiliated Hospital of Guangzhou Medical University,Guangdong Province,Shenzhen,China
3. Department of Histology and Embryology, Key Laboratory for Regenerative Medicine of the Ministry of Education, Institute of Fetal-Preterm Labor Medicine, Medical College of Jinan University,Guangzhou,China
4. Guangzhou Institute of Dermstology,Guangzhou,China
纸质出版日期:2016,
网络出版日期:2015-10-29,
Scan for full text
Shi, Jp., Li, Sx., Ma, Zl. et al. Acute and sub-chronic toxicity of tetrandrine in intravenously exposed female BALB/c mice., Chin. J. Integr. Med. 22, 925–931 (2016). https://doi.org/10.1007/s11655-015-2303-2
Jian-ping Shi, Shui-xiu Li, Zheng-lai Ma, et al. Acute and sub-chronic toxicity of tetrandrine in intravenously exposed female BALB/c mice[J]. Chinese Journal of Integrative Medicine, 2016,22(12):925-931.
Shi, Jp., Li, Sx., Ma, Zl. et al. Acute and sub-chronic toxicity of tetrandrine in intravenously exposed female BALB/c mice., Chin. J. Integr. Med. 22, 925–931 (2016). https://doi.org/10.1007/s11655-015-2303-2 DOI:
Jian-ping Shi, Shui-xiu Li, Zheng-lai Ma, et al. Acute and sub-chronic toxicity of tetrandrine in intravenously exposed female BALB/c mice[J]. Chinese Journal of Integrative Medicine, 2016,22(12):925-931. DOI: 10.1007/s11655-015-2303-2.
To evaluate the acute and sub-chronic toxicity of intravenously administered tetrandrine (TET) in female BALB/c mice. The median lethal dose (LD50) of intravenously administered TET was calculated in mice using Dixon's up-and-down method. In the acute toxicity study
mice were intravenously administered with TET at a single dose of 20
100
180
260 and 340 mg/kg
respectively and were evaluated at 14 days after administration. In the sub-acute toxicity study
mice were intravenously administered various doses of TET (30
90 and 150 mg/kg) each day for 14 consecutive days. Clinical symptoms
mortality
body weight
serum biochemistry
organ weight and histopathology were examined at the end of the experiment
as well as after a 1-week recovery period. LD50 was found to be 444.67±35.76 mg/kg. In the acute toxicity study
no statistically signifificant differences in body weight
blood biochemistry
or organ histology were observed between the administration and control groups when mice were intravenously administered with single dose at 20
100
180
260 and 340 mg/kg of TET (P >0.05). In the sub-acute toxicity study
no signifificant changes in body weight
biochemistry and organ histology were observed with up to 90 mg/kg of TET compared with the control group (P >0.05)
however
in the 150 mg/kg administered group
TET induced transient toxicity to liver
lungs and kidneys
but withdrawal of TET can lead to reversal of the pathological conditions. The overall fifindings of this study indicate that TET is relatively non-toxic from a single dose of 20
100
180
260 or 340 mg/kg
and that up to 90 mg/kg daily for 14 consecutive days can be considered a safe application dose.
To evaluate the acute and sub-chronic toxicity of intravenously administered tetrandrine (TET) in female BALB/c mice. The median lethal dose (LD50) of intravenously administered TET was calculated in mice using Dixon's up-and-down method. In the acute toxicity study
mice were intravenously administered with TET at a single dose of 20
100
180
260 and 340 mg/kg
respectively and were evaluated at 14 days after administration. In the sub-acute toxicity study
mice were intravenously administered various doses of TET (30
90 and 150 mg/kg) each day for 14 consecutive days. Clinical symptoms
mortality
body weight
serum biochemistry
organ weight and histopathology were examined at the end of the experiment
as well as after a 1-week recovery period. LD50 was found to be 444.67±35.76 mg/kg. In the acute toxicity study
no statistically signifificant differences in body weight
blood biochemistry
or organ histology were observed between the administration and control groups when mice were intravenously administered with single dose at 20
100
180
260 and 340 mg/kg of TET (P >0.05). In the sub-acute toxicity study
no signifificant changes in body weight
biochemistry and organ histology were observed with up to 90 mg/kg of TET compared with the control group (P >0.05)
however
in the 150 mg/kg administered group
TET induced transient toxicity to liver
lungs and kidneys
but withdrawal of TET can lead to reversal of the pathological conditions. The overall fifindings of this study indicate that TET is relatively non-toxic from a single dose of 20
100
180
260 or 340 mg/kg
and that up to 90 mg/kg daily for 14 consecutive days can be considered a safe application dose.
Tetrandrinefemale BALB/c miceacute and sub-chronic toxicityChinese Medicine
Tetrandrinefemale BALB/c miceacute and sub-chronic toxicityChinese Medicine
Lu JJ, Bao JL, Chen XP, Huang M, Wang YT. Alkaloids isolated from natural herbs as the anticancer agents. Evid Based Complement Alternat Med 2012;2012:485042.
Wang TH, Wan JY, Gong X, Li HZ, Cheng Y. Tetrandrine enhances cytotoxicity of cisplatin in human drug-resistant esophageal squamous carcinoma cells by inhibition of multidrug resistance-associated protein 1. Oncol Rep 2012;28:1681–1386.
Sun YF, Wink M. Tetrandrine and fangchinoline, bisbenzylisoquinoline alkaloids from Stephania tetrandra can reverse multidrug resistance by inhibiting P-glycoprotein activity in multidrug resistant human cancer cells. Phytomedicine 2014;21:1110–1119.
Zhang H, Gao A, Li F, Zhang G, Ho Hl, Liao W. Mechanism of action of tetrandrine, a natural inhibitor of Candida albicans drug efflux pumps. J Pharm Soc Jpn 2009;129:623–630.
Zhang H, Wang K, Zhang G, Ho HI, Gao A. Synergistic anti-candidal activity of tetrandrine on ketoconazole: an experimental study. Planta Med 2010;76:53–61.
Guo H, Xie SM, Li SX, Song YJ, Lv XL, Zhang H. Synergistic mechanism for tetrandrine on fluconazole against Candida albicans through the mitochondrial aerobic respiratory metabolism pathway. J Med Microbiol 2014;63:988–996.
Wang K, Zhang H, Jiang H, Shi J, GAO A, He H, et al. In vivo study on tetrandrine as a synergist to fluconazole in murine model of vaginal candidiasis. Chin J Zoonoses (Chin) 2007;23:474–478.
Shi JP, Zhang H, Zhang Z, Gao A, Wang K. Clinical investigation on the synergistic effect of tetrandrine on the antifungal activity of fluconazole for Vulvovaginal candidiasis. Chin J Zoonoses (Chin) 2009;25:1121–1123.
Shi JP, Zhang H, Zhang ZD, Zhang GH, Gao AL, Xiang SB. Synergistic effects of tetrandrine on the antifungal activity of topical ketoconazole cream in the treatment of dermatophytoses: a clinical trial. Chin J Integr Med 2011;17:499–504.
Dai CL, Xiong HY, Tang LF, Zhang X, Liang YJ, Zeng MS, et al. Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice. Cancer Chemother Pharmacol 2007;60:741–750.
Jin H, Li L, Zhong D, Liu J, Chen X, Zheng J. Pulmonary toxicity and metabolic activation of tetrandrine in CD-1 mice. Chem Res Toxicol 2011;24:2142–2152.
Gong X, Luo FL, Zhang L, Li HZ, Wu MJ, Li XH, et al. Tetrandrine attenuates lipopolysaccharide induced fulminant hepatic failure in D-galactosamine-sensitized mice. Int Immunopharmacol 2010;10:357–363.
Dixon WJ. The up-and-down method for small samples. J Am Stats Assoc 1965;60:967–978.
Yu Y, Li Y, Wang W, Jin M, Du Z, Li Y, et al. Acute toxicity of amorphous silica nanoparticles in intravenously exposed ICR mice. PLoS One 2013;8:e61346.
Parasuraman S, Sujithra J, Syamittra B, Yeng WY, Ping WY, Muralidharan S, et al. Evaluation of sub-chronic toxic effects of petroleum ether, a laboratory solvent in Sprague- Dawley rats. J Basic Clin Pharm 2014;5(4):89–97.
Zhao H, Luo F, Li H, Zhang L, Yi Y, Wan J. Antinociceptive effect of tetrandrine on LPS-induced hyperalgesia via the inhibition of IKKβ phosphorylation and the COX-2/PGE pathway in mice. PLoS One 2014;9:e94586.
Chen Y, Chen JC, Tseng SH. Tetrandrine suppresses tumor growth and angiogenesis of gliomas in rats. Int J Cancer 2009;15:2260–2269.
Chen Y, Tsai YH, Tseng SH. The potential of tetrandrine as a protective agent for ischemic stroke. Molecules 2011;16:8020–8032.
Fernandes MA, Custódio JB, Santos MS, Moreno AJ, Vicente JA. Tetrandrine concentrations not affecting oxidative phosphorylation protect rat liver mitochondria from oxidative stress. Mitochondrion 2006;6:176–185.
Feng D, Mei Y, Wang Y, Zhang B, Wang C, Xu L. Tetrandrine protects mice from concanavalin A-induced hepatitis through inhibiting NF-kappaB activation. Immunol Lett 2008;121:127–133.
Qi XM, Miao LL, Cai Y, Gong LK, Ren J. ROS generated by CYP450, especially CYP2E1, mediate mitochondrial dysfunction induced by tetrandrine in rat hepatocytes. Acta Pharmacol Sin 2013;34:1229–1236.
Cai Y, Qi XM, Gong LK, Liu LL, Chen FP, Xiao Y, et al. Tetrandrine-induced apoptosis in rat primary hepttocytes is initiated from mitochondria: caspases and endonuclease G (Endo G) pathway. Toxicology 2006;218:1–12.
Filomeni G, Rotilio G, Ciriolo MR. Cell signalling and the glutathione redox system. Biochem Pharmacol 2002;64:1057–1064.
Irie M, Sohda T, Iwata K, Kunimoto H, Fukunaga A, Kuno S, et al. Levels of the oxidative stress marker γ-glutamyltranspeptidase at different stages of nonalcoholic fatty liver disease. J Int Med Res 2012;40:924–933.
0
浏览量
0
Downloads
1
CSCD
关联资源
相关文章
相关作者
相关机构